World PulseNow
Newsletter

Alnylam pulls heart drug TV ad amid FDA crackdown

Investing.com•Thursday, October 2, 2025 at 2:52:33 PM
NegativeFinancial Markets
Alnylam pulls heart drug TV ad amid FDA crackdown
Alnylam Pharmaceuticals has decided to pull its television advertisement for a heart drug following increased scrutiny from the FDA. This move highlights the ongoing tension between pharmaceutical companies and regulatory bodies, especially as the FDA intensifies its efforts to ensure that drug marketing is both truthful and not misleading. The decision may impact Alnylam's visibility and sales, raising questions about the future of direct-to-consumer advertising in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System
Read Original

Was this article worth reading? Share it

Recommended Readings
F.D.A. Approves a New Generic Abortion Pill
The New York Times2 hours ago
F.D.A. Approves a New Generic Abortion Pill
PositiveFinancial Markets
The FDA has approved a new generic abortion pill, marking a significant step in expanding access to reproductive healthcare. This approval is crucial as it provides more options for individuals seeking abortion services, potentially reducing costs and increasing availability. The decision reflects ongoing efforts to ensure that safe and effective healthcare options are accessible to all, especially in light of recent legislative changes affecting reproductive rights.
Read full article
via The New York Times
Taysha Gene Therapies stock soars after FDA breakthrough therapy designation
Investing.com10 hours ago
Taysha Gene Therapies stock soars after FDA breakthrough therapy designation
PositiveFinancial Markets
Taysha Gene Therapies has received a breakthrough therapy designation from the FDA, causing its stock to soar. This designation is significant as it can expedite the development and review process for new treatments, highlighting the company's potential in the gene therapy sector. Investors are optimistic about the future of Taysha, as this recognition could lead to faster access to innovative therapies for patients.
Read full article
via Investing.com
SS Innovations completes key study for surgical robot FDA submission
Investing.com10 hours ago
SS Innovations completes key study for surgical robot FDA submission
PositiveFinancial Markets
SS Innovations has successfully completed a crucial study that paves the way for their surgical robot's submission to the FDA. This milestone is significant as it brings the company closer to introducing innovative robotic solutions in surgery, which could enhance precision and patient outcomes. The advancement in surgical technology is not only a win for SS Innovations but also a promising development for the healthcare industry, potentially transforming surgical procedures.
Read full article
via Investing.com
Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101
Investing.com11 hours ago
Fortress Biotech stock faces setback as FDA issues CRL for CUTX-101
NegativeFinancial Markets
Fortress Biotech's stock has taken a hit following the FDA's issuance of a Complete Response Letter (CRL) for its drug CUTX-101. This setback is significant as it delays the potential approval of a treatment that many hoped would address unmet medical needs. Investors are understandably concerned about the implications for the company's future and its ability to bring innovative therapies to market.
Read full article
via Investing.com
Vanda and FDA agree on framework to resolve drug disputes
Investing.coma day ago
Vanda and FDA agree on framework to resolve drug disputes
PositiveFinancial Markets
Vanda Pharmaceuticals and the FDA have reached a significant agreement on a framework to resolve disputes related to drug approvals. This collaboration is crucial as it aims to streamline the approval process, ensuring that patients have timely access to necessary medications. By establishing clear guidelines, both parties hope to reduce conflicts and enhance the overall efficiency of drug development, ultimately benefiting public health.
Read full article
via Investing.com
Novartis gets FDA approval for oral CSU treatment Rhapsido
Investing.com2 days ago
Novartis gets FDA approval for oral CSU treatment Rhapsido
PositiveFinancial Markets
Novartis has received FDA approval for Rhapsido, an oral treatment for chronic spontaneous urticaria (CSU). This is significant as it offers a new option for patients suffering from this condition, which can severely impact quality of life. With Rhapsido now available, patients may experience relief from symptoms more effectively, marking a positive advancement in the treatment landscape.
Read full article
via Investing.com
Novartis receives FDA approval for oral CSU treatment Rhapsido
Investing.com2 days ago
Novartis receives FDA approval for oral CSU treatment Rhapsido
PositiveFinancial Markets
Novartis has received FDA approval for its oral treatment Rhapsido for chronic spontaneous urticaria (CSU), marking a significant advancement in allergy management. This approval is crucial as it provides patients with a new option to manage their symptoms effectively, potentially improving their quality of life. The introduction of Rhapsido could change the landscape of CSU treatment, offering hope to those who struggle with this condition.
Read full article
via Investing.com
Zoetis stock rises after FDA conditionally approves screwworm drug
Investing.com2 days ago
Zoetis stock rises after FDA conditionally approves screwworm drug
PositiveFinancial Markets
Zoetis has seen a significant rise in its stock value following the FDA's conditional approval of its new screwworm drug. This approval is a major milestone for the company, as it opens up new avenues for addressing a critical agricultural pest that affects livestock. The positive market reaction reflects investor confidence in Zoetis's innovative approach to animal health, which could lead to increased sales and a stronger position in the pharmaceutical industry.
Read full article
via Investing.com
Latest from Financial Markets
Two killed in attack at Manchester synagogue
Financial Times33 minutes ago
Two killed in attack at Manchester synagogue
NegativeFinancial Markets
A tragic attack at a Manchester synagogue has left two people dead, with police identifying the perpetrator as a British citizen of Syrian descent. This incident has sparked outrage and condemnation, particularly from political leaders like Keir Starmer, who denounced the act as terrorism. Such violence not only affects the immediate victims and their families but also raises concerns about safety and community relations in the UK, highlighting the ongoing challenges of addressing extremism.
Read full article
via Financial Times
Earnings call transcript: SolarBank sees revenue decline but improves gross margin in Q4 2025
Investing.com35 minutes ago
Earnings call transcript: SolarBank sees revenue decline but improves gross margin in Q4 2025
NeutralFinancial Markets
In its latest earnings call, SolarBank reported a decline in revenue for Q4 2025, yet managed to improve its gross margin, indicating a potential shift towards more efficient operations. This is significant as it highlights the company's ability to adapt in a challenging market, which could bode well for future profitability and investor confidence.
Read full article
via Investing.com
Maison Solutions issues $3 million convertible note, plans World Coin acquisition
Investing.com37 minutes ago
Maison Solutions issues $3 million convertible note, plans World Coin acquisition
PositiveFinancial Markets
Maison Solutions has announced the issuance of a $3 million convertible note, signaling its intent to acquire World Coin. This move is significant as it highlights Maison's strategic growth plans and commitment to expanding its portfolio in the cryptocurrency sector, which could enhance its market position and attract more investors.
Read full article
via Investing.com
Kadant increases revolving credit facility to $750 million and extends maturity
Investing.com40 minutes ago
Kadant increases revolving credit facility to $750 million and extends maturity
PositiveFinancial Markets
Kadant has successfully increased its revolving credit facility to $750 million and extended its maturity, a move that strengthens its financial position and provides greater flexibility for future investments. This development is significant as it allows Kadant to better manage its capital and pursue growth opportunities, reflecting confidence in its business strategy and market potential.
Read full article
via Investing.com
Opinion | Volkswagen Gets What It Paid For
The Wall Street Journal40 minutes ago
Opinion | Volkswagen Gets What It Paid For
NegativeFinancial Markets
Volkswagen is currently grappling with a significant work stoppage that has financial implications for the company. This situation arises after VW welcomed a union last year, highlighting the complexities of labor relations in the automotive industry. The costly halt in production not only affects VW's operations but also raises questions about the future of labor negotiations and the balance between corporate interests and worker rights.
Read full article
via The Wall Street Journal
SurgePays notifies CFO Anthony Evers his contract will not be renewed
Investing.com42 minutes ago
SurgePays notifies CFO Anthony Evers his contract will not be renewed
NegativeFinancial Markets
SurgePays has informed its Chief Financial Officer, Anthony Evers, that his contract will not be renewed, marking a significant shift in the company's leadership. This decision raises questions about the company's future direction and financial strategy, as Evers has been a key figure in navigating its recent challenges. Stakeholders will be watching closely to see how this change impacts SurgePays' operations and overall performance.
Read full article
via Investing.com